Related Links Educational Materials About Clinical Trials Clinical Trials Questions to Ask Your Doctor Drug Information from MedlinePlus

Alternate Title
Basic Trial Information
Trial Description
     Purpose
     Eligibility
     Treatment/Intervention
Trial Contact Information
Registry Information

Alternate Title

Phase II Study of Neoadjuvant Paclitaxel and Carboplatin Followed By Surgery and Adjuvant Paclitaxel and Carboplatin in Patients With Stage III or IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Basic Trial Information

Phase	Type	Status	Age	Sponsor	Protocol IDs
Phase II	Treatment	Completed	Not specified	NCI	SWOG-S0009 S0009, NCT00008138

Trial Description

Purpose:

Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug or combining chemotherapy with surgery may kill more tumor cells.

Phase II trial to study the effectiveness of combination chemotherapy and surgery in treating patients who have stage III or stage IV ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer.

Eligibility:

Eligibility criteria include the following:

• No previous biological therapy or chemotherapy for this cancer
• No previous radiation therapy to the pelvis for this cancer
• For more information about the eligibility criteria for this trial, refer to the Health Professional version.

Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

Treatment/Intervention:

Patients will receive infusions of paclitaxel and carboplatin every 3 weeks for three courses. Within 5 weeks of the last course, some patients will undergo surgery to remove the tumor. Within 5 weeks of surgery, some patients will receive an infusion of paclitaxel followed by an intraperitoneal infusion of carboplatin on day 1, and an intraperitoneal infusion of paclitaxel on day 8. Treatment may be repeated every 4 weeks for up to six courses. Patients will receive follow-up evaluations every 3 months for 1 year, every 6 months for 2 years, and once a year for up to 5 years.

Important:

For more details about this trial, refer to the Health Professional version of the trial summary.

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.

Trial Contact Information

Trial Lead Organizations

Southwest Oncology Group

Amy Tiersten, MD, Protocol chair		Ph: 212-731-5349

Registry Information
Official Title		Phase II Evaluation Of Neoadjuvant Chemotherapy, Interval Debulking Followed By Intraperitoneal Chemotherapy In Women With Stage III And IV Epithelial Ovarian Cancer, Fallopian Tube Cancer Or Primary Peritoneal Cancer
Trial Start Date		2001-03-15
Trial Completion Date		2008-11-19
Registered in ClinicalTrials.gov		NCT00008138
Date Submitted to PDQ		2000-11-20
Information Last Verified		2006-01-10
NCI Grant/Contract Number		U10-CA32102

Back to Top